Sionna Therapeutics presents preclinical data on CFTR modulators at the ECFS conference in Milan.
Quiver AI Summary
Sionna Therapeutics, Inc. announced that preclinical data on its novel cystic fibrosis (CF) treatment candidates, SION-451 and SION-719, will be presented at the European Cystic Fibrosis Society’s conference in Milan from June 4-7, 2025. The presentation will explore how these NBD1 stabilizers can synergize with CFTR modulators like galicaftor and SION-109 to effectively correct the CFTR protein's function in individuals with the ΔF508 mutation. The presentation is scheduled for June 6, 2025, and will emphasize Sionna's mission to develop innovative therapies that significantly improve clinical outcomes for people with CF. More details about the findings will be available on Sionna's website following the event.
Potential Positives
- Sionna Therapeutics will present significant preclinical data at the European Cystic Fibrosis Society Conference, showcasing potential advancements in cystic fibrosis treatment.
- The oral presentation highlights a collaborative approach with a pipeline of novel CFTR modulators, indicating strong research and development efforts within the company.
- The company aims to address a major genetic mutation (F508del) affecting cystic fibrosis, which could lead to substantial improvements in patient care and quality of life.
Potential Negatives
- The press release does not provide any new positive data from clinical trials, which may lead to concerns about the efficacy and progression of their therapies.
- Details on the safety and efficacy of the drug candidates mentioned are not disclosed, which may raise doubts among investors about their viability.
- Highlighting preclinical data instead of clinical trial results may signal that the company is still far from regulatory approval and market readiness.
FAQ
What is Sionna Therapeutics' mission?
Sionna Therapeutics aims to revolutionize cystic fibrosis treatment by developing novel medicines that normalize CFTR protein function.
When will the European Cystic Fibrosis Conference take place?
The conference will be held from June 4-7, 2025, in Milan, Italy.
What is the focus of the oral presentation at the conference?
The presentation will discuss preclinical data on NBD1 stabilizers in combination with CFTR modulators for treating cystic fibrosis.
Who will present the findings at the conference?
Gregory Hurlburt, Ph.D., Co-Founder and Senior Vice President of Discovery Research at Sionna, will present the findings.
Where can I find more information about Sionna's science presentations?
Information will be available under the "Scientific Presentations" section on Sionna's website on the day of the event.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SION Insider Trading Activity
$SION insiders have traded $SION stock on the open market 7 times in the past 6 months. Of those trades, 7 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $SION stock by insiders over the last 6 months:
- CAPITAL MANAGEMENT, L.P. RA has made 2 purchases buying 1,125,000 shares for an estimated $20,250,000 and 0 sales.
- GP A, LLC TPG purchased 1,125,000 shares for an estimated $20,250,000
- ADVISORS LLC ORBIMED purchased 550,000 shares for an estimated $9,900,000
- PETER A. THOMPSON purchased 550,000 shares for an estimated $9,900,000
- BRUCE BOOTH purchased 60,000 shares for an estimated $1,080,000
- VENTURE FUND XI, L.P. ATLAS purchased 60,000 shares for an estimated $1,080,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Full Release
WALTHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that preclinical data assessing combinations of Sionna’s nucleotide-binding domain 1 (NBD1) stabilizers, SION-451 and SION-719, with complementary Sionna CFTR modulators, galicaftor (SION-2222) and SION-109, will be featured in an oral presentation at the European Cystic Fibrosis Society’s (ECFS) 48 th European Cystic Fibrosis Conference, being held June 4-7, 2025 in Milan, Italy.
Details of the oral presentation are as follows:
Abstract Title:
Stabilizers of CFTR NBD1 synergize with galicaftor (SION-2222) or SION-109 to enable full correction of ΔF508-CFTR
Abstract Number:
WS19.01
Presenting Author:
Gregory Hurlburt, Ph.D., Co-Founder and Senior Vice President, Discovery Research, Sionna
Session Title:
WS19 - Upstream/downstream: new therapies for people with cystic fibrosis
Date and Time:
Friday, June 6, 2025, 5:00-5:15 p.m. CET/11:00 -11:15 a.m. ET
The presentation will be made available the day of the event under the “Scientific Presentations” section within the Science page of Sionna’s website at https://www.sionnatx.com/our-science/ .
About Sionna Therapeutics
Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for CF by developing novel medicines that normalize the function of the CFTR protein. Sionna’s goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide-binding domain 1 (NBD1), which Sionna believes is central to potentially unlocking dramatic improvements in clinical outcomes and quality of life for people with CF. Leveraging more than a decade of the co-founders’ research on NBD1, Sionna is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in NBD1. Sionna is also developing a portfolio of complementary CFTR modulators that are designed to work synergistically with its NBD1 stabilizers to improve CFTR function. For more information about Sionna, visit www.sionnatx.com.
Sionna intends to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Company’s Investor Relations website, in addition to following the Company’s press releases, SEC filings, public conference calls, presentations, and webcasts.
Media Contact
Adam Daley
CG Life
212.253.8881
[email protected]
Investor Contact
Juliet Labadorf
[email protected]
